Liothyronine

Generic Name
Liothyronine
Brand Names
Cytomel, Np Thyroid
Drug Type
Small Molecule
Chemical Formula
C15H12I3NO4
CAS Number
6893-02-3
Unique Ingredient Identifier
06LU7C9H1V
Background

Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmaceuticals and FDA approved in 1956.

Indication

Liothyronine is officially approved for the following indications:

In general terms, exogenous liothyronine is used to replace insufficient hormonal production and restore T3 plasma levels.
...

Associated Conditions
Autonomy of thyroid gland, Hyperthyroidism, Hypothyroidism, Myxedema coma, Thyroid Cancer, Euthyroid Goitre, Myxedema pre-coma
Associated Therapies
Supplemental or replacement therapy
Clinical Trials
Related News

Mechanistic Study of Subclinical Hypothyroidism In the Elderly

First Posted Date
2015-03-26
Last Posted Date
2021-03-09
Lead Sponsor
University of Pennsylvania
Target Recruit Count
14
Registration Number
NCT02399475
Locations
🇺🇸

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Liothyronine and Heart Failure. The Long Term Effect of Liothyronine on Left Ventricular Ejection Fraction (LVEF)

Not Applicable
Completed
Conditions
Heart Failure
Low T3 Syndrome
Interventions
Drug: Liothyronine
First Posted Date
2011-11-29
Last Posted Date
2019-07-16
Lead Sponsor
Jens Faber
Target Recruit Count
21
Registration Number
NCT01481402
Locations
🇩🇰

Herlev Hospital, Dept. of Endocrinology, Herlev, Denmark

Acceleration and Relapse Prevention With Triiodothyronine (T3) as an Adjunct to Electroconvulsive Therapy (ECT)

Completed
Conditions
Depression
Interventions
Drug: T3
First Posted Date
2011-02-18
Last Posted Date
2012-05-11
Lead Sponsor
Mayo Clinic
Target Recruit Count
29
Registration Number
NCT01299337
Locations
🇺🇸

Mayo Clinic Department of Psychiatry and Psychology, Rochester, Minnesota, United States

Study of T3 for the Treatment of Fibromyalgia

Not Applicable
Completed
Conditions
Fibromyalgia
Interventions
Drug: T3
First Posted Date
2009-05-19
Last Posted Date
2017-07-14
Lead Sponsor
Stanford University
Target Recruit Count
51
Registration Number
NCT00903877
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Effect of T4-T3 Combination Therapy Versus T4 Monotherapy in Patients With Hypothyroidism

Phase 4
Completed
Conditions
Quality of Life
Depression
Interventions
Drug: Triiodothyronine
First Posted Date
2007-09-19
Last Posted Date
2007-09-19
Lead Sponsor
Copenhagen University Hospital at Herlev
Target Recruit Count
59
Registration Number
NCT00531713
Locations
🇩🇰

Dept of endocrinology , Herlev Hospital, Herlev, Denmark

Combined Levothyroxine/Liothyronine Supplementation in Hypothyroid Patients With Brain Tumors

Not Applicable
Terminated
Conditions
Hypothyroidism
Brain Tumor
Interventions
Drug: Levothyroxine
Drug: Liothyronine
First Posted Date
2007-06-20
Last Posted Date
2013-06-24
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
12
Registration Number
NCT00488644
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Sequential Tranylcypromine (TC), TC + Dextroamphetamine and TC + Triiodothyronine for Refractory Depression

First Posted Date
2006-02-27
Last Posted Date
2012-04-27
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
31
Registration Number
NCT00296686
Locations
🇺🇸

Depression Evaluation Service - New York State Psychiatric Institute, New York, New York, United States

Study of T3 on the Incidence of Atrial Fibrillation in Patients Undergoing Cardiac Surgery

Phase 1
Completed
Conditions
Atrial Fibrillation
First Posted Date
2006-02-09
Last Posted Date
2008-05-20
Lead Sponsor
Northwell Health
Target Recruit Count
280
Registration Number
NCT00289367
Locations
🇺🇸

North Shore University Hospital, Manhasset, New York, United States

Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer

Not Applicable
Completed
Conditions
Thyroid Cancer
First Posted Date
2005-09-22
Last Posted Date
2014-04-09
Lead Sponsor
Patrice Perron
Target Recruit Count
70
Registration Number
NCT00223158
Locations
🇨🇦

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada

Thyroid Medication and Antidepressants for Treating Major Depression

First Posted Date
2005-09-21
Last Posted Date
2015-11-17
Lead Sponsor
Emory University
Target Recruit Count
153
Registration Number
NCT00208702
Locations
🇺🇸

Emory University, Atlanta, Georgia, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy